Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Laboratory Corp. of America Holdings    LH

Delayed Quote. Delayed  - 08/24 10:02:03 pm
136.32 USD   -1.27%
08/23 LABORATORY OF A : LabCorp’s Acquisition of Sequenom Clears Ant..
08/15 KNOWLES : The Boulder Group Arranges Sale of Net Lease LabCorp Offic..
08/09 LABORATORY OF A : LabCorp Commences Cash Tender Offer for All Outsta..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Laboratory Corp. of America Holdings : LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/13/2012 | 10:05pm CEST

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2012 to September 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 7, 2012, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $1.50 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is August 26, 2012. The payment of contingent cash interest is expected to be made on September 11, 2012.

About LabCorp®

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its specialized labs and the LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine Sciences. LabCorp conducts clinical trials testing through its Esoterix Clinical Trials Services. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com.

This press release contains forward-looking statements. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2011, and subsequent SEC filings.

LabCorp
Stephen Anderson, 336-436-5274
www.labcorp.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LABORATORY CORP. OF AMERIC
08/23 LABORATORY OF AMERICA : LabCorp’s Acquisition of Sequenom Clears Antitrust..
08/22 LABORATORY OF AMERICA : Sources Sought Notice - Electronic Surveillance System f..
08/18 LABORATORY OF AMERICA : Sources Sought Notice - D-- Sources Sought Notice/Reques..
08/15 KNOWLES : The Boulder Group Arranges Sale of Net Lease LabCorp Office Property
08/09 LABORATORY OF AMERICA : LabCorp Commences Cash Tender Offer for All Outstanding ..
08/02 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
08/02 LABORATORY OF AMERICA : LabCorp Announces the Availability of the CDC Zika MAC-E..
08/02 LABORATORY OF AMERICA : LabCorp to Acquire Sequenom for $302 Million
08/01 INVESTIGATION FOR INVESTORS OVER POT : SQNM) Announced
07/29 LABORATORY OF AMERICA : Sequenom, Inc. Acquired by LabCorp for $302 Million
More news
Sector news : Healthcare Facilities & Services - NEC
08/18DJNestlé Reports Subdued Sales Growth
08/02DJFRESENIUS MEDICAL CARE KGAA : Lifts Profit Outlook After Strong North America Pe..
07/29DJFRESENIUS SE KGAA : 2Q 2016 -- Forecast
07/29DJFRESENIUS MEDICAL CARE KGAA : 2Q 2016 -- Forecast
07/28DJMARKET SNAPSHOT : Stocks Fall As Telecom Sells Off, Oil Tumbles
More sector news : Healthcare Facilities & Services - NEC
News from SeekingAlpha
08/24 Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2016 Updat..
08/23 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q2 2016 Upda..
08/22 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update
08/11 7 INTRIGUING HEALTHCARE GROWTH STOCK : Part 2
08/11 INC RESEARCH : Right Way To Monetize The Best Of CRO Industry
Advertisement
Financials ($)
Sales 2016 9 395 M
EBIT 2016 1 577 M
Net income 2016 748 M
Debt 2016 5 060 M
Yield 2016 -
P/E ratio 2016 18,68
P/E ratio 2017 15,93
EV / Sales 2016 2,04x
EV / Sales 2017 1,86x
Capitalization 14 125 M
More Financials
Chart LABORATORY CORP. OF AMERIC
Duration : Period :
Laboratory Corp. of Americ Technical Analysis Chart | LH | US50540R4092 | 4-Traders
Full-screen chart
Technical analysis trends LABORATORY CORP. ...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 150 $
Spread / Average Target 8,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David P. King Chairman, President & Chief Executive Officer
Glenn A. Eisenberg Chief Financial Officer, Treasurer & Executive VP
Mark Elliott Brecher Chief Medical Officer & Senior Vice President
Lance V. Berberian Chief Information Officer & Senior Vice President
Marcia T. Eisenberg Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LABORATORY CORP. OF AM..11.67%14 125
HCA HOLDINGS INC10.85%28 387
FRESENIUS MEDICAL CARE..3.69%28 308
DAVITA HEALTHCARE PART..-6.11%13 542
UNIVERSAL HEALTH SERVI..1.67%11 834
QUEST DIAGNOSTICS INC18.75%11 744
More Results